Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan

Factors impacting the efficacy of venlafaxine extended release 75–225 mg/day in patients with major depressive disorder: exploratory post hoc subgroup analyses of a randomized, double-blind, placebo-controlled study in Japan

Yoshinori Watanabe,1 Yuko Asami,2 Yoko Hirano,2 Kazuhiko Kuribayashi,3 Rio Itamura,4 Takayuki Imaeda4 1Himorogi Psychiatric Institute, Tokyo, Japan; 2Medical Affairs, Pfizer Essential Health, Pfizer Japan Inc., Tokyo, Japan; 3Clinical Statistics, Pfizer Japan Inc., Tokyo, Japan; 4Clinical Research,...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Watanabe Y, Asami Y, Hirano Y, Kuribayashi K, Itamura R, Imaeda T
Format: article
Langue:EN
Publié: Dove Medical Press 2018
Sujets:
venlafaxine
Hamilton Rating Scale for Depression (HAM-D)
subgroup
major depressive disorder (MDD)
Montgomery–Asberg Depression Rating Scale (MADRS)
Neurosciences. Biological psychiatry. Neuropsychiatry
RC321-571
Neurology. Diseases of the nervous system
RC346-429
Accès en ligne:https://doaj.org/article/91b2e89a07b044f78192ed42d2096ed6
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/91b2e89a07b044f78192ed42d2096ed6

Documents similaires